These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3133149)

  • 1. Abnormal pharmacokinetics of flecainide in a "nonresponder".
    van Gelder IC; Crijns HJ; van Wijk LM; van Gilst WH; Lie KI
    Clin Cardiol; 1988 May; 11(5):353-5. PubMed ID: 3133149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of oral dosage and pharmacokinetic analysis of flecainide in horses.
    Ohmura H; Hiraga A; Aida H; Takahashi T; Nukada T
    J Vet Med Sci; 2001 May; 63(5):511-4. PubMed ID: 11411495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Atrial flutter with 1:1 AV conduction during intravenous flecainide treatment].
    Heldal M; Orning OM
    Tidsskr Nor Laegeforen; 1989 Aug; 109(23):2309-10. PubMed ID: 2505404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias.
    Nathan AW; Camm AJ; Bexton RS; Hellestrand KJ
    Clin Cardiol; 1987 May; 10(5):317-22. PubMed ID: 3109795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Pharmacokinetic and Electrocardiographic Effects of Intratracheal and Intravenous Administration of Flecainide in Anesthetized Pigs.
    Stocco FG; Evaristo E; Silva AC; de Antonio VZ; Pfeiffer J; Rangachari N; Belardinelli L; Verrier RL
    J Cardiovasc Pharmacol; 2018 Sep; 72(3):129-135. PubMed ID: 29923887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reduction of auricular fibrillation and tachycardia using intravenous flecainide].
    Cohen-Solal A; Juliard JM; Jaeger P; Farinotti P; Dahan M; Charlier P; Boujon B; Aumont MC
    Arch Mal Coeur Vaiss; 1987 Jul; 80(8):1290-6. PubMed ID: 3120666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal intractable atrial flutter successfully treated with intravenous flecainide.
    Suzumura H; Nitta A; Ono M; Arisaka O
    Pediatr Cardiol; 2004; 25(2):154-6. PubMed ID: 14681740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudo infarction ECG pattern occurring during intravenous treatment with flecainide acetate.
    van Aubel KJ; Ruiter JH; Arnold AE; Burgersdijk C
    Eur Heart J; 1992 Jan; 13(1):137-9. PubMed ID: 1577021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the anti-arrhythmia effect of intravenous flecainide in supraventricular tachyarrhythmias].
    Garre L; Alvarez A; Cianciulli T; Quiroga J; Califano J; Mautner B
    Arch Inst Cardiol Mex; 1989; 59(3):241-4. PubMed ID: 2506843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic variability of flecainide assessed by QRS changes.
    Padrini R; Piovan D; Busa M; al-Bunni M; Maiolino P; Ferrari M
    Clin Pharmacol Ther; 1993 Jan; 53(1):59-64. PubMed ID: 8422742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics.
    Till JA; Shinebourne EA; Rowland E; Ward DE; Bhamra R; Haga P; Johnston A; Holt DW
    Br Heart J; 1989 Aug; 62(2):133-9. PubMed ID: 2504263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients.
    Frandsen F; Pless P; Mickley H; Møller M
    Acta Cardiol; 1990; 45(5):351-7. PubMed ID: 1704167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of intravenous flecainide in critically ill patients.
    Sangrador G; Sánchez-Alcaraz A; Rodriguez M; Ibáñez P
    J Clin Pharm Ther; 1989 Aug; 14(4):309-14. PubMed ID: 2507556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of flecainide acetate in patients with severe renal impairment.
    Williams AJ; McQuinn RL; Walls J
    Clin Pharmacol Ther; 1988 Apr; 43(4):449-55. PubMed ID: 3128417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects.
    Sihm I; Hansen FA; Rasmussen J; Pedersen AK; Thygesen K
    Eur Heart J; 1990 Feb; 11(2):145-8. PubMed ID: 2107078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism.
    Tennezé L; Tarral E; Ducloux N; Funck-Brentano C
    Clin Pharmacol Ther; 2002 Aug; 72(2):112-22. PubMed ID: 12189358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation.
    Deneer VH; Lie-A-Huen L; Kingma JH; Proost JH; Gossen SA; Stuurman A; Uytdehaag GM; Dunselman PH; Brouwers JR
    Eur J Clin Pharmacol; 2004 Dec; 60(10):693-701. PubMed ID: 15619132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of correlations between the main pharmacokinetic parameters and physiopathological factors of flecainide in the elderly].
    Michel P; Grellet J; Saux MC
    Therapie; 1991; 46(3):179-82. PubMed ID: 1724326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of atrial paralysis during the use of intravenous flecainide acetate].
    Tognarini S; Pardini E
    Cardiologia; 1989 Aug; 34(8):725-9. PubMed ID: 2514041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone.
    Funck-Brentano C; Becquemont L; Kroemer HK; Bühl K; Knebel NG; Eichelbaum M; Jaillon P
    Clin Pharmacol Ther; 1994 Mar; 55(3):256-69. PubMed ID: 8143391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.